In this comprehensive session, we explore the Chapter 18A regime introduced in 2018 that allows pre-revenue biotech companies to list on the Main Board without meeting the usual profit or revenue tests. The presentation covers the rapid growth of China’s biotech sector, the evolution of the HKEX biotech listing framework, detailed eligibility and suitability criteria (including Core Product requirements, sophisticated investor investment, minimum market capitalisation of HK$1.5 billion, enhanced working capital rules, and intellectual property ownership), listing document disclosure obligations, and the additional continuing obligations that apply post-listing. Recent developments such as the TECH consultation channel, confidential filing option, inclusion in Stock Connect, and updates to public float requirements are also discussed.

Whether you are a biotech company considering an HKEX listing, an investor evaluating Chapter 18A stocks, or a legal professional advising on biotech IPOs, this webinar provides practical guidance and the latest regulatory insights from one of Hong Kong’s most experienced IPO lawyers.

Watch the full recording to understand exactly what it takes for a pre-revenue biotech company to successfully list in Hong Kong today.